Camp4 Therapeutics (CAMP) Interest Expenses (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Interest Expenses of $56000.0 for Q1 2026, up 102.34% sequentially from -$2.4 million in Q4 2025, and down 95.07% YoY from $1.1 million in Q1 2025.
Camp4 Therapeutics (CAMP) Interest Expenses (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Interest Expenses for 4 years, with the latest figure at $56000.0 in Q1 2026.
- Quarterly Interest Expenses fell 95.07% year-over-year to $56000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$327000.0 (down 181.95% YoY) and the FY2025 annual result came in at $76.1 million, up 17.28% from the prior year.
- Interest Expenses improved to $56000.0 in Q1 2026 per CAMP's latest filing, from -$2.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $10.4 million in Q3 2024 and troughed at -$2.5 million in Q4 2024.
- A 4-year average of $1.6 million and a median of $755000.0 in 2023 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 1271.26% in 2024, down 3100.0% in 2024.
- Over 4 years, Interest Expenses stood at $83000.0 in 2023, then plunged by 3100.0% to -$2.5 million in 2024, then rose by 3.82% to -$2.4 million in 2025, then jumped by 102.34% to $56000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $56000.0, -$2.4 million, and $876000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | 2.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.48 Mn |
| Jun 30, 2026 | 2.48 Mn |
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | -2.40 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Sep 30, 2025 | 876,000.00 |
| Sep 30, 2025 | 876,000.00 |
| Jun 30, 2025 | 7.55 Mn |
| Jun 30, 2025 | 7.55 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | -2.49 Mn |
| Dec 31, 2024 | -2.49 Mn |
| Sep 30, 2024 | 10.35 Mn |
| Sep 30, 2024 | 10.35 Mn |
| Jun 30, 2024 | 650,000.00 |
| Jun 30, 2024 | 650,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |